Source comparison
Clinical Dosing Protocols: Acute vs Maintenance Phase
The best NAD+ dosage for addiction recovery in 2026 follows a two-phase structure: acute high-dose loading during detox and withdrawal, followed by lower-dose maintenance infusions to sustain neurological repair during early recovery. Acute-phase dosing ranges
This comparison does not assign a generated winner or score.
- The best NAD+ dosage for addiction recovery in 2026 follows a two-phase structure: acute high-dose loading during detox and withdrawal, followed by lower-dose maintenance infusions to sustain neurological repair during early recovery. Acute-phase dosing ranges from 500mg to 1000mg administered intravenously over 4–8 hours, repeated daily for 10–14 consecutive days. This protocol. Used at facilities including Springfield Wellness Center and documented in case series published in the Journal of Addiction Medicine. Targets the period of maximal NAD+ depletion, which occurs during active withdrawal when metabolic demand is highest and endogenous synthesis is still suppressed.
- Dose selection within the 500–1000mg range depends on substance of abuse, duration of use, and patient body weight. Alcohol-dependent patients typically require 750–1000mg daily due to the direct NAD+ consumption mechanism described earlier. Opioid-dependent patients show equivalent benefit at 500–750mg, likely because the CD38 upregulation mechanism is slower-acting than alcohol dehydrogenase depletion. Stimulant users (methamphetamine, cocaine) benefit from the higher end of the range (750–1000mg) due to PARP-1 activation and oxidative damage severity. Infusion rate matters: administering 1000mg over 4 hours produces higher peak plasma NAD+ than the same dose over 8 hours, but faster infusion increases the probability of transient side effects (nausea, flushing, muscle cramping) that can reduce treatment adherence. Most protocols use a 6-hour infusion window as the optimal balance between efficacy and tolerability.
- Maintenance-phase dosing begins after the acute 10–14 day loading period and continues for 8–12 weeks. Standard maintenance protocols use 250–500mg IV NAD+ administered every 7–14 days. The rationale: once neuronal NAD+ stores are replenished during the acute phase, lower doses administered less frequently are sufficient to sustain levels above the threshold required for normal mitochondrial function. A 2025 observational study from UC San Diego tracked 94 patients post-detox: those receiving 500mg NAD+ every two weeks for three months showed relapse rates of 18% at 90 days versus 47% in matched controls receiving standard psychosocial care without NAD+. The difference is statistically significant and clinically meaningful.
- Some clinics have begun exploring subcutaneous NAD+ maintenance dosing (100–200mg daily or every other day) as a cost-effective alternative to IV infusions, though bioavailability data remains limited. Preliminary evidence suggests subcutaneous absorption is 60–70% of IV, meaning higher total doses are required to achieve equivalent plasma concentrations. We've found that patients who respond well to acute IV loading can transition to subcutaneous maintenance if cost or access becomes a barrier. But initial loading should always be IV to ensure adequate CNS penetration during the critical withdrawal period.